Amgen is axing obesity candidate AMG 786 and going all in on later-stage asset MariTide. | Amgen is axing obesity candidate AMG 786 and going all in on later-stage asset MariTide. Read this story
Amgen is axing obesity candidate AMG 786 and going all in on later-stage asset MariTide. | Amgen is axing obesity candidate AMG 786 and going all in on later-stage asset MariTide. Read this story
More from Fierce Biotech | Amgen Obesity obesity drugs Eli Lilly Novo Nordisk Wegovy Mounjaro R&D Biotech Fierce Biotech Homepage Earnings NASDAQ:AMGN